FCFatemeh Chalabianloo

Fatemeh Chalabianloo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatemeh Chalabianloo has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fruit Smoothie Supplementation and Inflammatory Biomarkers in Individuals Receiving Opioid Agonist Therapy: A Multicenter Randomized Controlled Trial

    by Lise M. Thomassen, Elaheh J. Arjmand, Karl T. Druckrey-Fiskaaen, Einar Furulund, Jørn Henrik Vold, Rune Blomhoff, Hege Berg Henriksen, Tesfaye Madebo, Jan T. Daltveit, Fatemeh Chalabianloo, et al.

    Background/Objectives: People with opioid dependence often experience elevated inflammatory markers and poor dietary habits. Evidence from other populations suggests that higher fruit and vegetable intake may reduce inflammation. This multicenter randomized controlled trial investigates whether offering a daily supplementation of 250 mL of fruit smoothie for 16 weeks to people undergoing opioid agonist treatment (OAT) can reduce inflammation biomarkers. Methods: 319 individuals were randomized to receive either a daily supplement of 250 mL of fruit smoothie in addition to standard OAT or standard OAT alone over 16 weeks. The primary outcome was the log-transformed change in high-sensitivity C-reactive protein (hs-CRP). Secondary outcomes included changes in cytokines (IL-8, IL-1RA, and MCP-1) and leukocyte counts. Results: No between-group differences were observed in changes in hs-CRP levels (0.96 (0.77; 1.21) mg/L), leukocytes (0.99 (0.93; 1.05)109/L), IL-8 (1.10 (0.84; 1.46) pg/mL), MCP-1 (0.94 (0.80; 1.11) pg/mL), and IL-1RA (1.06 (0.91; 1.23) pg/mL). High levels of inflammatory markers were observed at baseline in both the intervention group and the control group. Conclusions: After 16 weeks of offering fruit smoothie supplementation in patients receiving OAT, we did not detect a between-group reduction in inflammation markers such as hs-CRP, IL-8, MCP-1, IL-1RA, and leukocyte counts, under the achieved level of delivery and exposure. Nonetheless, persistently high levels of inflammatory markers were observed in this study.

  • Need for evidence-based approach to benzodiazepine dependence in opioid agonist treatment

    by Fatemeh Chalabianloo, John Fredrik Askjer, Andreas Wahl Blomkvist, Kjetil Samuel Dale, Christine Sundal, Beathe Hauge Rønning, Wasifa Sofia Javed Butt, Silvia Zavenova, Anne Gry Ørmen, Christina Dahl Andersen, et al.

  • Open Access

    Association between thyroidea function and opioid agonist therapy: a prospective cohort study from Norway

    by Anne Taraldsen Heldal, Jorn Henrik Vold, Kristin Viste, Fatemeh Chalabianloo, Gunnar Mellgren, Kjell Arne Johansson, Lars Thore Fadnes

    Background: Opioid agonist therapy (OAT) is an essential treatment for opioid dependency. However, OAT may lead to endocrinopathy, which may impair the tolerability of treatment. Although the risk of disturbed regulation of the adrenal and gonadal axes has been extensively studied, less is known about how long-term opioid use and corresponding risk factors influence the thyroid axis. The objective of this study was to investigate associations between biomarkers of thyroid function and OAT medication as well as sociodemographic and clinical factors and concurrent use of illicit substances among patients receiving OAT. Methods: We used prospective data from 320 people receiving OAT in Bergen, Norway, from 2016 through 2023. All had 2 health assessments, including serum measurements of TSH. Descriptive statistics and a linear mixed model with coefficient and 95% CIs were performed to investigate the association between serum TSH (measured in mIU/L) and OAT medication as well as age, sex, substance use patterns, injecting use, housing status, and educational attainment at first assessment and over time. Results: Median serum TSH at first assessment in the study population was 1.8 mIU/L (interquartile range: 1.2). No association between OAT medications, sociodemographic, or clinical factors and serum TSH was found at first assessment and over time. Conclusion: The median serum TSH was within the recommended range among people receiving OAT. No association between OAT treatment and thyroid insufficiency was found. This indicates that screening for thyroid function beyond symptomatic assessment is probably not needed among patients receiving OAT.

  • Open Access

    Impact of dextroamphetamine substitution on the use of illicit amphetamines in adults with amphetamine dependence: a study protocol for the multicentre double blind randomised controlled trial ATLAS4Dependence

    by Fatemeh Chalabianloo, Lars T Fadnes, Jon Mordal, Olav Spigset, Else-Marie Løberg, Anne Halmøy, Torgeir Gilje Lid, Christina Dahl Andersen, Jan Tore Daltveit, Jõrg Assmus, et al.

    Introduction: There is limited evidence on how to effectively treat individuals from marginalised populations with dependence on amphetamine and/or methamphetamine (collectively referred to hereafter as amphetamine dependence). The disease burden is extremely high in this population, especially related to psychiatric comorbidities, cardiovascular complications, injection-related infections and poor social functioning. ATLAS4Dependence is a multi-centre randomised, placebo-controlled, double-blind trial that will investigate the effectiveness and safety of substitution treatment with dextroamphetamine compared with placebo in people with amphetamine dependence. Methods and analysis: The trial will recruit 226 adult patients in several outpatient clinics in Norway. Inclusion criteria comprise individuals with amphetamine dependence, defined as use on three or more days per week during the past 28 days, who currently inject or have formerly injected drugs. This includes individuals both with and without comorbid opioid dependence, as well as those currently receiving or not receiving opioid agonist treatment. Participants will be randomly assigned 1:1 to receive either dextroamphetamine or placebo for 12 weeks. Flexible doses within the range of 30–120 mg daily will be provided based on individual assessments. The participants in both arms will be offered standard psychosocial and medical follow-up in accordance with current clinical practice. The endpoint assessments will be conducted at 12 weeks with weekly self-reports and safety assessments and a follow-up assessment at 52 weeks. The primary objective of the study is to assess the impact of 12 weeks daily prescribed oral dextroamphetamine versus placebo on the use of illicit amphetamines as well as on the total amount of amphetamines used (including both illicit and prescribed sources). Secondary outcomes are the differences between the groups at 12 weeks regarding psychological distress, symptoms of psychosis, quality of life, cardiovascular risk factors, injection-related infections, executive functioning, attention-deficit hyperactivity disorder-related symptoms, sleep, violence risk, fatigue, symptoms of craving and withdrawal, treatment retention, days of use of illicit amphetamines and use at 4 weeks and 8 weeks during the intervention period, use of other illicit substances and alcohol, as well as a cost-effectiveness analysis (using private economy, criminal activity and health service utilisation) and a qualitative approach to assess overall experiences with the study intervention. Analysis and reporting will follow the Consolidated Standards of Reporting Trials guidelines. All tests will be two-sided. Descriptive results and the estimated effectiveness will be presented with 95% CIs. The difference between the groups at the primary time point (at the end of the 12-week trial) will be assessed using χ 2 test (for use of illicit amphetamines measured by monthly urine tests) and Analysis of Covariance (ANCOVA) (for weekly self-reported total amount of amphetamines). Analyses for the primary endpoint will be undertaken on an intention-to-treat basis and reported on as such, but sensitivity analyses with per protocol analyses will also be presented. Ethics and dissemination: The study is approved by European Medicines Agency, Clinical Trial Information System (CTIS). Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals. Trial registration number: CTIS 2023-510404-44-00.


  • Open Access

    Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR

    by Fatemeh Chalabianloo, Lars Thore Fadnes, Jörg Assmus, Jon Mordal, Kristin K. Solli, Kjetil S. Dale, Christina D. Andersen, Silvia Zavenova, Beathe H. Rønning, Andreas W. Blomkvist, et al.

    Background: There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment; however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches. A randomized controlled trial will be conducted to compare the efficacy and safety of stabilizing agonist treatment using prescribed benzodiazepines with standard treatment in reducing illicit benzodiazepine use. Methods: The target sample is 108 participants at outpatient OAT clinics in six Norwegian cities/counties (Bergen/Vestland, Tønsberg/Vestfold, Skien/Telemark, Fredrikstad/Østfold, Tromsø/Troms, and Lillestrøm/Akershus). The main inclusion criteria are benzodiazepine dependence of ≥ 5 years, using ≥ 5 days a week during the last month, and previous attempts at tapering. Participants will be randomly assigned to receive either a 26-week benzodiazepine stabilizing treatment (15–30 mg diazepam or 50–100 mg oxazepam daily), or a 20-week tapering using the same medications and equivalent initial dosages. All participants will be given access to consultations from OAT therapists with psychosocial follow-up in accordance with current clinical practice. The primary outcome is the use of illicit benzodiazepines assessed by observed urinary tests at week 24. Secondary outcomes include mental health symptoms, quality of life, cognitive performance, violence risk, other substance use, treatment retention, and life satisfaction. Additionally, the study will assess treatment-related adverse events as well as the cost-effectiveness of the intervention. Discussion: This is the first randomized controlled trial of benzodiazepine agonist treatment for benzodiazepine dependence. The research project will assess efficacy and safety of stabilizing treatment with prescribed benzodiazepines compared to benzodiazepine tapering and discontinuation regarding use of illicit benzodiazepines and accordingly well-being of patients with concurrent benzodiazepine and opioid dependence undergoing OAT. If the intervention is found to be efficacious and safe, it will be considered one of the options to standard treatment for this patient group. Trial registration: EU trial number: EudraCT: 2021–004981-37. Registered on December 13, 2021.


  • Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis

    by Seenae Eum, Nicholas P. Vernacchia, Nia Doughty, Sahar Mehrzad, Andrew H. Talal, Fatemeh Chalabianloo, Evan D. Kharasch

    Confusion regarding methadone metabolism exists, hampering optimal clinical use. A systematic review was conducted to assess the impacts of cytochrome P450 (CYP) genetic polymorphisms on methadone outcomes. MEDLINE, EMBASE, Web of Science, PsycINFO, and CENTRAL were searched to identify studies reporting methadone dose-adjusted plasma concentrations, clearance, maintenance dose, or treatment response in relation to CYP polymorphisms in humans. ROBINS-I was used to evaluate risk of bias in included studies. Each outcome was synthesized for each CYP using the ratio of means or odds ratio as the effect size measure. Ten, two, fourteen, and five studies were included in the meta-analyses of the concentration, clearance, dose, and treatment response, respectively. The CYP2B6 c.516 G>T variant was robustly associated with (S)-methadone concentrations (GT+TTvs.GG: ratio of means (RoM) 1.40, p < 0.01) and clearance (GT+TTvs.GG: RoM 0.65, p < 0.01) but less with (R)- or (R,S)-methadone. The CYP2B6 variant also affected methadone dose for opioid use disorder (GT+TTvs.GG: RoM 0.93, p = 0.04). CYP2C19, CYP2C9, CYP2D6, and CYP3A5 polymorphisms did not influence any of the assessed outcomes. CYP2B6 genetics had statistically significant impacts on (S)-methadone and less so on (R)-methadone exposure and clearance and was statistically significantly but not clinically meaningfully associated with dose requirements.


  • Open Access

    Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR

    by Fatemeh Chalabianloo, Lars Thore Fadnes, Jörg Assmus, Jon Mordal, Kristin K Solli, Kjetil S Dale, Christina D Andersen, Christian Ohldieck, Else-Marie Løberg, Kjell Arne Johansson

    Background There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment, however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches. A randomized controlled trial will be conducted to compare the efficacy and safety of stabilizing agonist treatment using prescribed benzodiazepines with standard treatment in reducing illicit benzodiazepine use. Methods The target sample is 108 participants at outpatient OAT clinics in five Norwegian cities/counties (Bergen/Vestland, Tønsberg/Vestfold, Skien/Telemark, Fredrikstad/Østfold and Tromsø/Troms). The main inclusion criteria are benzodiazepine dependence of ≥5 years, using ≥5 days a week during the last month, and previous attempts at tapering. Participants will be randomly assigned to receive either a 26-week benzodiazepine stabilizing treatment (15-30 mg diazepam or 50-100 mg oxazepam daily), or a 20-week tapering using the same medications and equivalent initial dosages. All participants will be given access to consultations from OAT therapists with psychosocial follow-up in accordance with current clinical practice. The primary outcome is the use of illicit benzodiazepines assessed by observed urinary tests at week 24. Secondary outcomes include mental health symptoms, quality of life, cognitive performance, violence risk, other substance use, treatment retention, and life satisfaction. Additionally, the study will assess treatment-related adverse events as well as the cost-effectiveness of the intervention. Discussion This is the first randomized controlled trial of benzodiazepine agonist treatment for benzodiazepine dependence. The research project will assess efficacy and safety of stabilizing treatment with prescribed benzodiazepines compared to benzodiazepine tapering and discontinuation regarding use of illicit benzodiazepines and accordingly well-being of patients with concurrent benzodiazepine and opioid dependence undergoing OAT. If the intervention is found to be efficacious and safe, it will be considered one of the options to standard treatment for this patient group. Trial registration EU trial number: EudraCT: 2021-004981-37. Registered on December 13, 2021

  • Open Access

    Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications

    by Fatemeh Chalabianloo, Lars Thore Fadnes, Kjell Arne Johansson, Gudrun Høiseth, Jørn Henrik Vold, Marianne K. Kringen, Olav Spigset, Jørgen G. Bramness

    Background: A considerable inter‐individual variability has been reported in the relationship between methadone doses applied and serum concentrations achieved in methadone maintenance treatment. However, the underlying causes for this variability are not fully understood.Objectives: We investigated the influence of genetic, pathophysiological and pharmacological factors on serum methadone concentration‐to‐dose ratio (CDR) and discussed the clinical implications of the findings.Methods: We used data from two retrospective laboratory databases and a prospective cohort study to investigate the impact on methadone CDR of hepatic cytochrome P450 enzyme system (CYP) genetic polymorphisms, age, sex, concomitant medication, liver fibrosis and body mass index through linear mixed model analyses.Findings: A positive association was found between CDR and the homozygous CYP2B6*6 genotype, concurrent treatment with CYP3A4 inhibitors and body mass index. CDR was lower among women and during concomitant use of CYP inducers. CDR was not associated with age or the degree of liver fibrosis in our investigations.Conclusions: This research work supports the need for individually tailored dosage considering the various factors that influence methadone CDR. The gained knowledge can contribute to reducing the risks associated with the treatment and optimizing the desired outcomes.


  • Open Access

    Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study

    by Jørn Henrik Vold, Anne Halmøy, Fatemeh Chalabianloo, Marianne Cook Pierron, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes

    Background: Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT) is scarce. This study examined ADHD symptoms using the ADHD self-report scale (ASRS) and the association between the ‘ASRS–memory’ and ‘ASRS–attention’ scores and substance use and sociodemographic characteristics among patients receiving OAT.Methods: We used data from assessment visits of a cohort of patients in Norway. In total, 701 patients were included from May 2017 to March 2022. All patients responded at least once to two ASRS questions assessing memory and attention, respectively. Ordinal regression analyses were performed to investigate whether the two obtained scores were associated with age, sex, frequent substance use, injecting use, housing status, and educational attainment at baseline, i.e., the first assessment, and over time. The results are presented as odds ratios (OR) with 95% confidence intervals (CI). Additionally, a subsample of 225 patients completed an extended interview, including the ASRS–screener and collection of registered mental disorder diagnoses from the medical records. Standard cutoffs were used to define the presence of each ASRS symptom or a positive ASRS–screener (‘ASRS–positive’).Results: At baseline, 428 (61%) and 307 (53%) patients scored over the cutoffs on the ‘ASRS–memory’ and ‘ASRS–attention,’ respectively. Frequent cannabis use was associated with higher ‘ASRS–memory’ (OR: 1.7, 95% CI: 1.1–2.6) and ‘ASRS–attention’ (1.7, 1.1–2.5) scores compared with less or no use at baseline, though reduced score on the ‘ASRS–memory’ over time (0.7, 0.6–1.0). At baseline, frequent stimulant use (1.8, 1.0–3.2) and low educational attainment (0.1, 0.0–0.8) were associated with higher ‘ASRS–memory’ scores. In the subsample fulfilling the ASRS–screener, 45% of the patients were ‘ASRS–positive,’ of whom 13% with a registered ADHD diagnosis.Conclusions: Our findings illustrate a relationship between the ASRS–memory and –attention scores and frequent cannabis and stimulant use. Furthermore, nearly half of the subsample was ‘ASRS–positive.’ Patients receiving OAT might benefit from being further assessed for ADHD, but improved diagnostic methods are required.